HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tyrogenex, Xcovery appoint Michael Webb CEO

This article was originally published in Scrip

Executive Summary

Tyrogenex and Xcovery, two privately held companies focused on the development of next-generation targeted therapeutics for cancer and ophthalmology, have named Michael D Webb as president and CEO of both companies. The boards of both companies appointed Mr Webb, who has been CEO of four biotechnology companies as well as chair of the MassBio industry organization. Most recently, he was president and CEO of Allegro Diagnostics, a venture-backed, molecular diagnostics company focused on lung cancer that was acquired by Veracyte in 2014. Sheridan Snyder, co-founder and former president and CEO of both companies, remains chair of the Xcovery board and a director on the Tyrogenex board. Tyrogenex and Xcovery share a common scientific legacy and management team. Xcovery is developing X-396, an anaplastic lymphoma kinase inhibitor for non-small cell lung cancer entering Phase III this year. Tyrogenex is developing X-82, an orally administered, dual VEGFR/PDGFR inhibitor for angiogenesis in oncology and wet age-related macular degeneration.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel